Monte Rosa Therapeutics, Inc. GLUE
10.82 USD +0.41 (+3.94%)
At closeNov 5, 2026, 6:07 AM EST
10.36 -0.46 -4.25%
Pre-market · Nov 5, 6:07 AM ET
10.07 Day range 11.08
9.68 52-week range 25.77
- YTD
- -30.99%
- 1 year
- -9.83%
Financial health
Altman Z-Score
1.73 Distress zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
2 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
C+2 / 5 overall
- DCF 5
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 3
- P/E 1
- P/B 2
Valuation
P/E -26.6×
FY 2019 5y median -7.1× FY 2025
P/S 8.3×
FY 2019 5y median 0.0× FY 2025
P/B 4.4×
FY 2019 5y median 2.3× FY 2025
P/FCF -37.4×
FY 2019 5y median -4.6× FY 2025
EV/EBITDA -29.9×
FY 2019 5y median -5.3× FY 2025
EV/Sales 7.6×
FY 2019 5y median 0.0× FY 2025
FCF Yield -2.7%
FY 2019 5y median -7.3% FY 2025
Profitability
Gross Margin 93.2%
FY 2019 5y median 0.0% FY 2025
Operating Margin -43.8%
FY 2019 5y median 0.0% FY 2025
Net Margin -31.2%
FY 2019 5y median 0.0% FY 2025
ROE -16.6%
FY 2019 5y median -32.6% FY 2025
ROIC -13.6%
FY 2019 5y median -28.4% FY 2025
ROA -8.6%
FY 2019 5y median -20.2% FY 2025
Growth (YoY)
Revenue 63.5%
FY 2019 FY 2025
Operating Income 33.2%
FY 2019 FY 2025
EPS (diluted) 39.8%
FY 2019 FY 2025
Free Cash Flow -172.3%
FY 2019 FY 2025
Financial Health
Current Ratio 6.1×
FY 2019 5y median 6.1× FY 2025
Quick Ratio 6.1×
FY 2019 5y median 6.1× FY 2025
Debt / Equity 0.2×
FY 2019 5y median 0.2× FY 2025
Net Debt / EBITDA 2.9×
FY 2019 5y median 2.9× FY 2025
Interest Coverage 0.0×
FY 2019 5y median 0.0× FY 2025
Dividends
Dividend Yield 0.0%
FY 2019 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2019 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31